Palmetto GBA, a Medicare administrative contractor that assesses molecular diagnostic technologies, has issued a draft local coverage determination for the Oncotype DXGenomic Prostate Score issued a draft LCD that recommends Medicare coverage for use of the test in qualified patients with favorable intermediate-risk prostate cancer.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
